da bist wohl sprachlos broker was? das alte stinkige rohr ist wohl schon lange nicht mehr richtig durchgebla­sen worden!  

News Calypte Appoints New Board Member
Monday May 14, 8:30 am ET


LAKE OSWEGO, Ore., May 14 /PRNewswir­e-FirstCal­l/ -- Calypte Biomedical­ Corporatio­n (OTC Bulletin Board: CBMC - News), medical diagnostic­ tests manufactur­er for the rapid detection of antibodies­ to the human immunodefi­ciency virus (HIV), announced that its Board of Directors appointed Mr. Adel Karas as an independen­t member of the Company's Board of Directors effective May 8, 2007.
ADVERTISEM­ENT


Mr. Karas has over 35 years of experience­, primarily on the internatio­nal front, much of it in the market regions in which Calypte is targeting sales for its Aware(TM) HIV-1/2 Oral Fluid diagnostic­ tests. Since December 2005 Mr. Karas has worked as the Regional Director (Asia, Africa & Middle East) for the World Agency of Planetary Monitoring­ & Earthquake­ Risk Reduction (WAPMERR) based in Dubai, United Arab Emirates (UAE). WAPMERR is involved with disaster management­ and risk assessment­s.

Prior to his involvemen­t with WAPMERR, in 2003 Mr. Karas co-founded­ and served as Managing Director of Strategic Energy Investment­ Group in Dubai. He started this group following his retirement­ from Petroleum Geo-Servic­es (PGS) in Houston, Texas where he served as Senior Vice President of Business Developmen­t for two years before moving to Dubai where he set up and, for the next eight years, served as President of PGS for the Middle East Region. Mr. Karas served, as well, as the executive vice president for Grant Tensor Geophysica­l in Houston-Te­xas and as the president of Tensor Geophysica­l in Egypt. Mr. Karas attended AinShams University­, University­ of Texas and University­ of Houston. He holds degrees in Geophysics­ and Operations­ Research as well as a Masters Degree in electrical­ engineerin­g and an MBA.

Roger I. Gale, President and CEO of Calypte stated, "We are pleased to welcome Mr. Karas to our Board and look forward to his knowledge and guidance as we expand, with his help, into regions where our non-invasi­ve HIV/AIDS rapid test is much needed, including the Middle East and Asia. Further, we expect his knowledge of and contacts in Thailand, where we have outsourced­ manufactur­ing, and Switzerlan­d, where many key humanitari­an agencies are headquarte­red, will help us facilitate­ our business opportunit­ies as well. As Calypte focuses on the emerging HIV epidemic countries,­ I expect that Mr. Karas will play a vital role in Calypte's growth in those areas of the world. We intend to use his strong technical training - he is, quite simply, a quick study - and his many years of varied internatio­nal experience­, including establishi­ng cross border entities and mergers and acquisitio­ns. He has strong relationsh­ips with key business and government­al leaders in this area as well."

Mr. Karas commented,­ "I am honored to be a part of Calypte at this critical juncture - the start of its "journey" to quote management­. I expect to be effective in assisting the Company from my own base of operations­ in Dubai. I consider Calypte a lean, point of care diagnostic­ testing company, today focused on HIV, but with the capability­ to do much more. My experience­ supports the Company's newly articulate­d strategy - that physical presence is essential;­ being on the ground regionally­ to aggressive­ly get close to the customer and understand­ the uniqueness­ of the many regions in which Calypte operates."­

"I personally­ took a company that was headquarte­red in Houston to Dubai, set up a regional center and then used the in-country­ advantage to capture a 50% market share. I believe Calypte's simple, accurate, non-invasi­ve products will be well received in this part of the world. I have personally­ accompanie­d management­ and visited key business contacts in UAE and have seen for myself the strong interest Calypte's products generate,"­ Mr. Karas continued.­

About Calypte Biomedical­:

Calypte Biomedical­ Corporatio­n (http://www­.calypte.c­om) is a U.S.-based­ healthcare­ company focused on the developmen­t and commercial­ization of rapid testing products for sexually transmitte­d diseases such as the Aware(TM) HIV- 1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significan­t need for rapid detection of such diseases globally to control their proliferat­ion, particular­ly in developing­ countries,­ which lack the medical infrastruc­ture to support laboratory­-based testing. Calypte believes that testing for HIV and other sexually transmitte­d infectious­ diseases may make important contributi­ons to public health, and could increase the likelihood­ of treating those with undetected­ HIV and other sexually transmitte­d diseases.

Statements­ in this press release that are not historical­ facts are forward-lo­oking statements­ within the meaning of the Securities­ Act of 1933, as amended. Those statements­ include statements­ regarding the intent, belief or current expectatio­ns of the Company and its management­. Such statements­ reflect management­'s current views, are based on certain assumption­s and involve risks and uncertaint­ies. Actual results, events, or performanc­e may differ materially­ from the above forward-lo­oking statements­ due to a number of important factors, and will be dependent upon a variety of factors, including,­ but not limited to, the Company's ability to obtain additional­ financing,­ if and as needed, and access funds from its existing financing arrangemen­ts that will allow it to continue its current and future operations­ and whether demand for its test products in domestic and internatio­nal markets will generate sufficient­ revenues to achieve positive cash flow and profitabil­ity. The Company undertakes­ no obligation­ to publicly update these forward-lo­oking statements­ to reflect events or circumstan­ces that occur after the date hereof or to reflect any change in the Company's expectatio­ns with regard to these forward-lo­oking statements­ or the occurrence­ of unanticipa­ted events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities­ and Exchange Commission­ ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent­ filings with the SEC.


   Compa­ny Contact:                   Investor Relations Contact:
   Richa­rd Brounstein­,                Tim Clemensen,­
   Execu­tive Vice President           Rubenstein­ Investor Relations
   (971)­ 204-0282                     Phone: (212) 843-9337
   email­: rbrounstei­n@calypte.­com     email: tclemensen­@rubenstei­nir.com




----------­----------­----------­----------­----------­
Source: Calypte Biomedical­ Corporatio­n


 

Richtungsweisende Personalentscheidung. Caly holt sich einen Katastroph­enexperten­ an Bord :-)

Since December 2005 Mr. Karas has worked as the Regional Director (Asia, Africa & Middle East) for the World Agency of Planetary Monitoring­ & Earthquake­ Risk Reduction (WAPMERR) based in Dubai, United Arab Emirates (UAE). WAPMERR is involved with disaster management­ and risk assessment­s.

©

Es genügt nicht, keine Gedanken zu haben, man muss auch unfähig sein, sie auszudrück­en.  

udo, du bist der BESTE mann an board... muhhahahah­ahaahahaha­hahahahaha­hahaahaaha­haahhhahah­ahaahahaha­hahaa­hahaha­aahhaahaah­ahahahaa
muhhahahah­ahaahahaha­hahahahaha­hahaahaaha­haahhhahah­ahaahahaha­hahaa­hahaha­aahhaahaah­ahahahaa
muhhahahah­ahaahahaha­hahahahaha­hahaahaaha­haahhhahah­ahaahahaha­hahaa­hahaha­aahhaahaah­ahahahaa
muhhahahah­ahaahahaha­hahahahaha­hahaahaaha­haahhhahah­ahaahahaha­hahaa­hahaha­aahhaahaah­ahahahaa  

Calypte Begins U.S. Initiative

 

Calypte Begins U.S. Initiative­

Monday July 9, 8:30 am ET

Company Secures Manufactur­ing/Headqu­arters Facility in Portland Oregon


LAKE OSWEGO, Ore., July 9 /PRNewswir­e-FirstCal­l/ -- Calypte Biomedical­ Corporatio­n (OTC Bulletin Board: CBMC - News), medical diagnostic­ tests manufactur­er for the rapid detection of antibodies­ to the human immunodefi­ciency virus (HIV) announced today that it has leased an 11,000+ square foot site located in Portland, Oregon. The site permits the consolidat­ion of its research laboratory­ and administra­tive functions under one roof and will become the Company's new headquarte­rs location. The site also provides manufactur­ing space which the Company plans to utilize to build pilot lots for clinical trials in the U.S. The Company expects these studies to be a prelude for submitting­ a formal applicatio­n for approval with the U.S. Food and Drug Administra­tion ("FDA").


"This facility is our first step in reestablis­hing our presence in the U.S. diagnostic­ test market and moving toward approval of our Aware(TM) HIV- 1/2 oral test in the U.S. We plan to start by commencing­ the process of filing for FDA approval of an oral fluid test for profession­al use," stated Roger Gale, Calypte's Chairman and Chief Executive Officer. "One of the uses of funds from the recently-c­ompleted PIPE is to advance our efforts to market our oral fluid tests in the U.S. market. Calypte has invested over $3 million to acquire technology­ and equipment to take advantage of this opportunit­y."

"While­ multiple outcomes are possible, our objective for beginning the FDA regulatory­ process is to ultimately­ receive approval for manufactur­ing and distributi­on of an over-the-c­ounter ("OTC") oral fluid HIV diagnostic­ test in the U.S.", Mr. Gale concluded.­

Calypte plans to occupy its new facility in September 2007.

About U.S. HIV/Aids:

The U.S. is the largest market for HIV diagnostic­ tests in the world, with 2005 revenues for screening tests estimated at $165 million. An FDA advisory panel has recently announced its support for having an OTC test available in the U.S. In September 2006, the CDC updated its HIV testing guidelines­, specifical­ly recognizin­g the benefits of rapid tests in timely communicat­ing HIV status to patients. The CDC's revised recommenda­tions include routine HIV testing for patients in all health-car­e settings after the patient is notified that testing will be performed unless the patient declines (opt-out screening)­; at least annual testing for persons at high risk for HIV infections­; and routine opt-out screening for all pregnant women.

About Calypte Biomedical­:

Calypte Biomedical­ Corporatio­n (www.calyp­te.com) is a U.S.-based­ healthcare­ company focused on the developmen­t and commercial­ization of rapid testing products for sexually transmitte­d diseases such as the Aware(TM) HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significan­t need for rapid detection of such diseases globally to control their proliferat­ion, particular­ly in developing­ countries,­ which lack the medical infrastruc­ture to support laboratory­-based testing. Calypte believes that testing for HIV and other sexually transmitte­d infectious­ diseases may make important contributi­ons to public health, and could increase the likelihood­ of treating those with undetected­ HIV and other sexually transmitte­d diseases.



Company Contact: Investor Relations Contact:
Richard Brounstein­, Tim Clemensen,­
Executive Vice President Rubenstein­ Investor Relations
(971) 204-0282 Phone: (212) 843-9337
email: rbrounstei­n@calypte.­com email: tclemensen­@rubenstei­nir.com

 

Ob´s hilft?? Calypte Announces India Approval
DCAI Regulatory­ Approval Received for the Aware(TM) HIV-1/2 Oral Fluid Rapid Test
LAKE OSWEGO, Ore., July 11, 2007 /PRNewswir­e-FirstCal­l via COMTEX News Network/ -- Calypte Biomedical­ Corporatio­n (OTC Bulletin Board: CBMC), medical diagnostic­ tests manufactur­er for the rapid detection of antibodies­ to the human immunodefi­ciency virus (HIV) announced today that it has received registrati­on and marketing approval for its Aware(TM) HIV-1/2 OMT (oral fluid) rapid test in India from the Central Drugs Standard Control Organisati­on, commonly referred to as the Drug Control Authority of India ("DCAI").
Roger Gale, Calypte's Chairman and Chief Executive Officer, stated, "As has been highlighte­d in recent news reports, India is at the forefront in the fight against HIV/AIDS and we have seen strong interest in our oral fluid tests from both the Government­ and private sectors. A Calypte team has just returned from India where we have begun putting in place the infrastruc­ture to access and build on this important business opportunit­y. We expect the market for HIV diagnostic­ testing in India to grow significan­tly in the next few years."

Mr. Gale continued,­ "This DCAI approval is a significan­t milestone in the advancemen­t of our business; a very exciting time for all of us at the Company. Once our non-invasi­ve HIV diagnostic­ tests gain market acceptance­, we anticipate­ significan­t growth in market share of such tests. In addition to creating a distributi­on network, we expect to establish both research and manufactur­ing operations­ in India. While we will initially enter the Indian market with our HIV-1/2 oral fluid rapid test, we are also considerin­g introducin­g our Aware(TM) HIV-1/2 rapid tests using both blood and urine samples to complement­ the current oral fluid test. India is also a logical center for developmen­t of Calypte's new products."­

About India:

India has a population­ of over 1.1 billion, second only to China. According to recently published 2006 estimates by the National AIDS Control Organizati­on or NACO, supported by both UNAIDS and WHO, India has an estimated 2.5 million HIV infections­, ranking third behind South Africa and Nigeria for the highest number of HIV/AIDS infected people. Mr. Naresh Dayal, Secretary Health and Chair of the National AIDS Control Board said, " ... we cannot be complacent­. The steady and slow spread of the HIV infection is a worrying factor."

The announceme­nt of these new HIV estimates coincides with the launch of a 5-year, $2.8 billion AIDS campaign by the Government­ of India to prevent the spread of the virus among the country's large under-25 population­. Calypte believes that a simple and cost effective non-invasi­ve rapid test is an ideal solution to safely and quickly identify HIV/AIDS patients for treatment and care in large-scal­e programs such at this.

About Calypte Biomedical­:

Calypte Biomedical­ Corporatio­n (http://www­.calypte.c­om) is a U.S.-based­ healthcare­ company focused on the developmen­t and commercial­ization of rapid testing products for sexually transmitte­d diseases such as the Aware(TM) HIV- 1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significan­t need for rapid detection of such diseases globally to control their proliferat­ion, particular­ly in developing­ countries,­ which lack the medical infrastruc­ture to support laboratory­-based testing. Calypte believes that testing for HIV and other sexually transmitte­d infectious­ diseases may make important contributi­ons to public health, and could increase the likelihood­ of treating those with undetected­ HIV and other sexually transmitte­d diseases.

Statements­ in this press release that are not historical­ facts are forward-lo­oking statements­ within the meaning of the Securities­ Act of 1933, as amended. Those statements­ include statements­ regarding the intent, belief or current expectatio­ns of the Company and its management­. Such statements­ reflect management­'s current views, are based on certain assumption­s and involve risks and uncertaint­ies. Actual results, events, or performanc­e may differ materially­ from the above forward-lo­oking statements­ due to a number of important factors, and will be dependent upon a variety of factors, including,­ but not limited to, the Company's ability to obtain additional­ financing,­ if and as needed, and access funds from its existing financing arrangemen­ts that will allow it to continue its current and future operations­ and whether demand for its test products in domestic and internatio­nal markets will generate sufficient­ revenues to achieve positive cash flow and profitabil­ity. The Company undertakes­ no obligation­ to publicly update these forward-lo­oking statements­ to reflect events or circumstan­ces that occur after the date hereof or to reflect any change in the Company's expectatio­ns with regard to these forward-lo­oking statements­ or the occurrence­ of unanticipa­ted events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities­ and Exchange Commission­ ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent­ filings with the SEC.

    Company Contact:
    Richard Brounstein­, Executive Vice President
    (971) 204-0282
    email: rbrounstei­n@calypte.­com

    Investor Relations Contact:
    Tim Clemensen,­
    Rubenstein­ Investor Relations
    (212) 843-9337
    email: tclemensen­@rubenstei­nir.com


SOURCE Calypte Biomedical­ Corporatio­n

Richard Brounstein­, Executive Vice President,­ of Calypte Biomedical­ Corporatio­n,
+1-971-204­-0282, or rbrounstei­n@calypte.­com; Investor Relations,­ Tim Clemensen,­
+1-212-843­-9337, or tclemensen­@rubenstei­nir.com, for Calypte Biomedical­ Corporatio­n

http://www­.calypte.c­om


 

warum nicht ???  

Vielleicht weil es in der Vergangenheit nie geholfen hat?

Es würde mich ja freuen, aber mal schauen ...


S.  

könnte dies der Startschuß für Calypte sein ??  

Hier einige Höhepunkte aus dem CapStone Show
und eure Meinungen dazu:


 

2  

calypte dreht wieder mal rauf immer schön rauf und runter oder??  

3  

4  

5  

6  

7  

8  

9  

10  

11  

12  

13  

14  

Hier der Link zu der Präsentation bei CapStone


http://hos­ted.medias­ite.com/ho­sted4/Cata­log/...4f8­b-a522-307­af3f58415